Fig. 4. B8C1ad has a longer therapeutic window than polyclonal antitoxin sera.

(A) Ten-day survival rates in mice challenged with BoNT/A1 (2 mipLD₅₀, intraperitoneally) and treated with B8C1ad (0.4 mg/kg, intraperitoneally) or antitoxin (1 U, intraperitoneally) after 3 hours (n = 20), 6 hours (n = 20), 8 hours (n = 20), 12 hours (n = 30), 16 hours (n = 20), or 20 hours (n = 30). (B) Ten-day survival rates in mice challenged with BoNT/A1 (2 mipLD₅₀, intraperitoneally) and treated with B8C1ad [0.3 mg/kg; intravenously (i.v.)] or antitoxin (1 U, intravenously) after 12 hours (n = 5), 16 hours (n = 5), or 20 hours (n = 5). (C) B8C1ad ED₅₀ values were determined in mice challenged with BoNT/A1 (2 mipLD₅₀, intraperitoneally) and treated with B8C1ad (0.003 to 0.40 mg/kg, intravenously) after 10 hours (n = 8 to 23 per dose). (D) Median clinical severity score (CSS) of groups in (C) with greater than 50% survival. (A), (C), and (D) represent the aggregate of at least three experiments; (B) represents the aggregate of two experiments. Additional details of statistical comparisons are presented in table S3. *P < 0.5, **P < 0.01, and ****P < 0.0001.